No-Spa (Drotaverine Hydrochloride)

Drotaverine Hydrochloride, the active ingredient in No‑Spa, is a phosphodiesterase inhibitor presented as an injectable solution for intramuscular and intravenous administration. It produces smooth‑muscle relaxation and is used to alleviate abdominal and gastrointestinal spasms, biliary and renal colic, dysmenorrhea, and urinary tract spasm in adult patients.

GNH USA supplies No‑Spa as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality‑assurance standards and supports regulatory compliance for each market through dedicated logistics and technical assistance.

No‑Spa acts on smooth‑muscle spasm disorders, providing relief in several gastrointestinal and urogenital conditions.

- Abdominal and gastrointestinal spasms: reduces pain and restores normal motility. - Biliary colic: relaxes biliary ducts to ease stone‑related pain. - Renal colic: alleviates ureteral smooth‑muscle contraction. - Dysmenorrhea: diminishes uterine muscle cramps during menstruation. - Urinary tract spasm: eases bladder and urethral smooth‑muscle irritation.

Adverse reactions may occur with any antispasmodic therapy.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Nausea: transient feeling of queasiness. - Dizziness: occasional light‑headedness. - Flushing: temporary redness of the skin. - Hypotension: mild drop in blood pressure.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypotension: marked blood pressure decrease leading to fainting. - Cardiac arrhythmia: irregular heart rhythm. - Hepatic dysfunction: abnormal liver enzyme elevations. - Blood dyscrasias: rare blood cell abnormalities.

Safety considerations should be observed before and during treatment.

- Pregnancy: safety not established; use only if clearly needed and prescribed. - Breastfeeding: weigh potential risks against benefits; consult a physician. - Renal impairment: monitor renal function and adjust therapy as needed. - Concomitant antihypertensives: observe for additive blood‑pressure lowering effects. - Known hypersensitivity: avoid use in patients with documented allergy to drotaverine or excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may modify therapeutic outcomes.

Major Interactions (Avoid): - Potent vasodilators: combined use can cause severe hypotension. - Other phosphodiesterase inhibitors: may increase risk of cardiovascular side effects. - Strong CYP450 inhibitors: could raise drotaverine plasma concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: monitor blood pressure for additive effects. - Diuretics: watch for electrolyte disturbances and blood‑pressure changes. - Additional antispasmodics: assess for cumulative smooth‑muscle relaxation.